These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38899981)

  • 1. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
    Avigan ZM; Joshua Richter Md
    Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
    Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
    Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
    [No Abstract]   [Full Text] [Related]  

  • 3. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
    Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
    Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
    Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
    J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
    Touzeau C; Le Gouill S; Mahé B; Boudreault JS; Gastinne T; Blin N; Caillon H; Dousset C; Amiot M; Moreau P
    Haematologica; 2017 Mar; 102(3):e112-e114. PubMed ID: 28057737
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
    Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
    Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.
    Basali D; Chakraborty R; Rybicki L; Rosko N; Reed J; Karam M; Schlueter K; Dysert H; Kalaycio M; Valent J
    Br J Haematol; 2020 Jun; 189(6):1136-1140. PubMed ID: 32012228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
    Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
    Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.
    Bal S; Giri S; Godby KN; Costa LJ
    Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
    Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
    Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
    Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
    Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
    [No Abstract]   [Full Text] [Related]  

  • 16. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.
    Soleimani A; Koka M; Singh ZN; Kesari V; Badros A
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e556-e559. PubMed ID: 32653454
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
    Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT; Dhodapkar MV; Nooka AK; Lonial S; Mitsiades CS; Kaufman JL; Boise LH
    Blood; 2021 Jul; 137(26):3604-3615. PubMed ID: 33649772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.
    Leung N; Thomé SD; Dispenzieri A
    Haematologica; 2018 Mar; 103(3):e135-e137. PubMed ID: 29351984
    [No Abstract]   [Full Text] [Related]  

  • 20. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.